A collaborative study between the Max Planck Institute of Psychiatry and the University of California, Irvine, explores the potential of pupillometry as a clinical test for identifying a specific subgroup of patients with major depressive disorder (MDD) characterized by anticipatory hypo-arousal related to anhedonia.
Principle findings showed that aflibercept 8 mg demonstrated similar improvements in BCVA and CST when compared to the 2 mg dose of aflibercept.
David A. Eichenbaum, MD, discusses the promising aspects of gene augmentation for treating common retinal diseases, addresses concerns about perpetual protein production, and considers the potential positive impact on patients by reducing treatment burdens.
David Eichenbaum, MD, discussed the status of the technology at the Retina 2024 meeting in Maui.
Glenn J. Jaffe, MD, discusses the multifactorial complexities of treating patients with geographic atrophy.
NIDEK Co. Ltd. has made a financial donation to Orbis International to support Orbis’s artificial intelligence (AI)-based screening services in Vietnam.
According to the company, MicroPine, currently in late phase III for pediatric progressive myopia, will complement Eyenovia’s commercial-stage asset, Mydcombi, as well as its pre-PDUFA candidate, APP13007.
The Annual Gala will be held on February 8 from 6 to 9 pm Pacific Standard Time.
David Hutton of Ophthalmology Times talks with Eric Donnenfeld, MD about his presentation "Small Aperture IOL for Irregular Corneas" at this year's Hawaiian Eye and Retina 2024 Meeting.
According to the Advanced Research Projects Agency for Health, its program aims to transplant human eyes and reestablish visual connection to the brain.
Patient selection is important.
David Hutton of Ophthalmology Times talks with William Trattler, MD, about his presentation "Toric IOL pearls for Correcting Lower Levels of Astigmatism" at this year's Hawaiian Eye and Retina 2024 Meeting.
Varun Chaudhary, MD, FRCSC, addressed the big questions in treating patients with retinal vascular diseases at the Retina 2024 meeting in Maui.
GreenMan app provides patients an opportunity to test drive various IOL options before cataract surgery via virtual and augmented reality.
The first step in management is increasing the time spent outside
The goal is to understand how individuals with CVI interact with their visual world
Vascular compromise is the most ominous early adverse event that can occur when a filler is unintentionally injected into a blood vessel.
David Hutton of Ophthalmology Times talks with Andrew Lee, MD, about his presentation "Neuro op mimics of thyroid eye disease" at this year's Hawaiian Eye and Retina 2024 Meeting.
According to a study by Johns Hopkins Children’s Center researchers, AI-driven cameras that take images of the back of the eye and require no eye drops can be used to close care gaps.
According to an American Academy of Ophthalmology news release, Edmond’s priorities during her term include addressing physician and staff shortages and protecting patient safety at a time when nonphysicians are trying to expand their scope of practice into eye surgery.
Company presenting data from the Phase II AAVIATE trial of suprachoroidal ABBV-RGX-314 for the treatment of wet age-related macular degeneration January 16 at the Hawaiian Eye and Retina 2024 Meeting.
The company is showcasing its lasers at the Hawaiian Eye and Retina 2024 meeting, being held January 13-19 at the Grand Wailea Resort in Maui.
Studies aim to develop a clinically useful biomarker of retinal capillary changes to monitor the development of a prevalent form of systemic vascular disease and cerebrovascular disease.
Because acetylcholinesterase inhibitors have anti-inflammatory effects, authors of the study wanted to determine if these drugs reduce the risk of AMD in patients with Alzheimer’s disease.
The GLYCO Phase 2 US clinical trial will evaluate AVD-104 for the management of diabetic macular edema (DME).
The VISUMAX 800 is the latest generation of Zeiss femtosecond lasers, and offers a reduced laser time when compared to its predecessors.
AR-15512, a topical transient receptor potential melastatin 8 agonist, is a first-in-class product candidate for the treatment of the signs and symptoms of dry eye disease. Alcon plans to file a New Drug Application for AR-15512 with the FDA in mid-2024.
According to the company, cyclosporine ophthalmic solution 0.1% is the first and only cyclosporine-based product for treating the signs and symptoms of dry eye disease.
Researchers at Indiana University School of Medicine will focus on providing a foundation for developing a new glaucoma therapeutic by testing human neurons and a regenerative therapy to rescue visual neurons from dying preclinically in human eyes under glaucoma conditions.
.png "Optometry Times"){kind=logo}
